M F Bath1, A Saratzis2, M Saedon3, D Sidloff4, R Sayers4, M J Bown4. 1. Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Leicester Royal Infirmary, Leicester, UK. Electronic address: michael.bath@doctors.org.uk. 2. Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Leicester Royal Infirmary, Leicester, UK. Electronic address: as875@le.ac.uk. 3. Department of Vascular Surgery, University Hospital Coventry and Warwickshire, Coventry, UK. 4. Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Leicester Royal Infirmary, Leicester, UK.
Abstract
BACKGROUND: Patients with abdominal aortic aneurysm (AAA) are at significant risk of cardiovascular (CV) events. Recent implementation of AAA-screening means thousands of patients are now diagnosed with small-AAA; however, CV risk factors are not always addressed. This study aimed at assessing and quantifying the CV characteristics of patients with small AAA following the introduction of screening programmes. METHODS: CV profiles of 384 men with a small AAA (<55 mm diameter) were assessed through the United Kingdom Aneurysm Growth Study (UKAGS), a nationwide prospective cohort study of men with small AAA. A prospective local cohort of an additional 142 patients with small AAA with available blood pressure (BP) and lipid profiles was also included and followed-up for 1 year. RESULTS: In the UKAGS population, 54% were current and 30% ex-smokers; 58% were hypertensive and 54% hypercholesterolaemic. In the local group, 54% were current and 40% were ex-smokers, and 94% were hypertensive. Patients were not more likely to receive CV medication after entering AAA surveillance in either group. All local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7). No change was seen in systolic BP levels between baseline and 1 year (140.9 mmHg vs. 142.5 mmHg, p=.435). A rise was seen in cholesterol (4.0 mmol-4.2 mmol, p<.0001) values at 1 year. CONCLUSIONS: This study suggests that patients with small AAA are at significant risk for developing CV events and this is not currently addressed, which is evident by the "high-risk" CV risk profiles of these patients despite being in AAA surveillance. Design and implementation of a CV risk reduction programme tailored for this population is necessary.
BACKGROUND: Patients with abdominal aortic aneurysm (AAA) are at significant risk of cardiovascular (CV) events. Recent implementation of AAA-screening means thousands of patients are now diagnosed with small-AAA; however, CV risk factors are not always addressed. This study aimed at assessing and quantifying the CV characteristics of patients with small AAA following the introduction of screening programmes. METHODS: CV profiles of 384 men with a small AAA (<55 mm diameter) were assessed through the United Kingdom Aneurysm Growth Study (UKAGS), a nationwide prospective cohort study of men with small AAA. A prospective local cohort of an additional 142 patients with small AAA with available blood pressure (BP) and lipid profiles was also included and followed-up for 1 year. RESULTS: In the UKAGS population, 54% were current and 30% ex-smokers; 58% were hypertensive and 54% hypercholesterolaemic. In the local group, 54% were current and 40% were ex-smokers, and 94% were hypertensive. Patients were not more likely to receive CV medication after entering AAA surveillance in either group. All local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7). No change was seen in systolic BP levels between baseline and 1 year (140.9 mmHg vs. 142.5 mmHg, p=.435). A rise was seen in cholesterol (4.0 mmol-4.2 mmol, p<.0001) values at 1 year. CONCLUSIONS: This study suggests that patients with small AAA are at significant risk for developing CV events and this is not currently addressed, which is evident by the "high-risk" CV risk profiles of these patients despite being in AAA surveillance. Design and implementation of a CV risk reduction programme tailored for this population is necessary.
Authors: H H S Kharagjitsing; J van Vooren; E G Brilman; T R Hendriksz; T van Gelder; E F H van Bommel Journal: Rheumatol Int Date: 2021-11-25 Impact factor: 2.631
Authors: Clare Oliver-Williams; Michael J Sweeting; Jo Jacomelli; Lisa Summers; Anne Stevenson; Tim Lees; Jonothan J Earnshaw Journal: Circulation Date: 2019-03-12 Impact factor: 29.690
Authors: Ify R Mordi; Rachael O Forsythe; Corry Gellatly; Zaid Iskandar; Olivia M McBride; Athanasios Saratzis; Rod Chalmers; Calvin Chin; Matthew J Bown; David E Newby; Chim C Lang; Jeffrey T J Huang; Anna-Maria Choy Journal: J Am Heart Assoc Date: 2019-10-09 Impact factor: 5.501
Authors: Maria Perissiou; Tom G Bailey; Zoe L Saynor; Anthony I Shepherd; Amy E Harwood; Christopher D Askew Journal: Exp Physiol Date: 2022-03-18 Impact factor: 2.858
Authors: Paul Welsh; Claire E Welsh; Pardeep S Jhund; Mark Woodward; Rosemary Brown; Jim Lewsey; Carlos A Celis-Morales; Frederick K Ho; Daniel F MacKay; Jason M R Gill; Stuart R Gray; S Vittal Katikireddi; Jill P Pell; John Forbes; Naveed Sattar Journal: Circulation Date: 2021-06-25 Impact factor: 29.690